This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Alexion Pharmaceuticals Inc (ALXN)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) 252.90M 254.82M 175.32M 97.03M
Operating Gains/Losses 764.00K -2.69M 615.00K 6.28M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -116.44M -72.87M -78.78M -59.24M
(Increase) Decrease in Inventories 126.00K -6.26M -12.18M -14.12M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 136.64M 61.72M 79.78M 47.46M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 23.48M 13.17M 15.03M 1.32M
Other Non-Cash Items 115.01M 84.72M 51.68M 31.82M
Net Cash From Continuing Operations 497.35M 410.61M 270.08M 160.91M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 497.35M 410.61M 270.08M 160.91M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 60.92M 0.00 94.46M 53.39M
Purchases of Property, Plant & Equipment -29.33M -21.85M -21.98M -12.84M
Acquisitions 0.00 -605.74M -105.89M 0.00
Purchases of Short-Term Investments -1.05B 0.00 0.00 -129.86M
Other Cash from Investing Activities -9.32M -4.00K -307.00K -2.00K
Cash Provided by Financing Activities
Net Cash From Investing Activities -1.03B -627.58M -33.72M -89.32M
Issuance of Debt 0.00 355.00M 60.00M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 71.28M 528.65M 35.76M 37.55M
Repayment of Long-Term Debt -36.00M -206.00M -60.73M -649.00K
Repurchase of Capital Stock -66.14M -11.55M 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 102.49M 279.00K 4.02M 1.97M
Net Cash From Financing Activities 71.64M 666.38M 39.05M 38.87M
Effect of Exchange Rate Changes -1.49M -768.00K -1.70M -482.00K
Net Change in Cash & Cash Equivalents -459.64M 448.64M 273.72M 109.97M

ALXN Alexion Pharmaceuticals Inc

Analysts Ratings for ALXN

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 12 12 12 11
Moderate Buy 1 1 1 1
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

Brokerage Partners

ALXN Chatter

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs